Skip to content

RNA: 15 Funds Holding, Catalyst in 50d | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›Avidity Biosciences Inc. (RNA)

Avidity Biosciences Inc.

RNA

Held by 15 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

15 funds opened new positions. Next phase3 readout (AOC 1001 (del-desiran)): Aug 2026.

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Share

BiotechnologyCEO: Kathleen GallagherIPO: 2026Website ↗

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

7.0/10

15 funds opened new positions●●

No recent insider activity●●

Phase3 readout in 50 days●●

Held by 15 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

15 specialist funds hold RNA with a Phase 3 in 50 days for AOC 1001 (del-desiran) (DM1, Myotonic Dystrophy, Myotonic Dystrophy 1)

+5 more upcoming catalysts

Eventide Asset Management Cormorant Asset Management Tang Capital Management RA Capital Management Commodore Capital Deerfield Management Avoro Capital Advisors Baker Bros. Advisors RTW Investments OrbiMed Advisors Deep Track Capital EcoR1 Capital Driehaus Capital Casdin Capital Boxer Capital

Fund Holdings

15 fund convergence

Eventide Asset Management

Cormorant Asset Management

Tang Capital Management

RA Capital ManagementHeld 7Q ↓

Commodore Capital

Deerfield Management

Avoro Capital Advisors

Baker Bros. Advisors

RTW Investments

OrbiMed Advisors

Deep Track Capital

Driehaus Capital

Position history (shares)

Eventide Asset Management

6Q

Cormorant Asset Management

5Q

RA Capital Management

7Q

Avoro Capital Advisors

6Q

RTW Investments

5Q

OrbiMed Advisors

6Q

EcoR1 Capital

5Q

Driehaus Capital

5Q

AI Signal

Eventide exits RNA ahead of a crowded catalyst schedule. The values-based fund liquidated its entire ~$37.8M position in Avidity Biosciences, stepping away despite a pipeline with meaningful near-term readouts — most notably the del-desiran (AOC 1001) Phase 3 data expected by August 2026 in DM1 and AOC 1044 Phase 2 data in Duchenne expected April 2027. The exit is notable given the 15-fund specialist consensus still holding the name, including Baker Bros., OrbiMed, RA Capital, and Deep Track — suggesting Eventide's departure may reflect mandate fit or ESG screening rather than a pipeline-driven thesis break, but the full liquidation warrants monitoring for any read-through on near-term data confidence.

Unlock full AI analysis — 14-day free trial

7 quarters

Position Trend

Feb 13, 2026

$37.8M

1 fund

Feb 17, 2026

$808.3M

5 funds

Mar 16, 2026

$393.5M

1 fund

May 15, 2026

$11.6M

1 fund

-44% total institutional value over 24 quarters

Short Interest

Float data divergenceHigh short interestSI declining 2 periods (-2.1%)

Short Shares

3.65M

Change

-2.1%

Days to Cover

17.2

Settlement

Jun 15, 2026

Short interest over 8 periods

Catalysts

Phase 2Q1 2023AOC 1001DM1, Myotonic Dystrophy 1, Myotonic DystrophyNCT05027269

Phase 2Q4 2024AOC 1044Duchenne Muscular Dystrophy, Exon 44NCT05670730

Phase 2Q3 2025PlaceboDM1, Muscular Dystrophies, Myotonic DystrophyNCT05479981

Phase 3Q3 2026AOC 1001 (del-desiran)DM1, Myotonic Dystrophy, Myotonic Dystrophy 1NCT06411288

Phase 2Q2 2027AOC 1044DMD, Duchenne Muscular Dystrophy, DuchenneNCT06244082

Phase 3Q2 2028AOC-1020Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular DystrophyNCT07038200

Primary: Quantitative Muscle Testing (QMT) composite score (Baseline through Week 78)Enrollment:Target 200Sites: 22RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2029AOC 1044Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Muscular Disorders, AtrophicNCT07587242

Phase 2Q2 2030AOC 1020FSHD, FSHD1, FSHD2NCT06547216

Primary: Incidence of treatment-emergent adverse events (Through study completion, up to Day 729)Enrollment:Target 84Sites: 17NON_RANDOMIZED, TREATMENT

Phase 3Q3 2030Del-desiran (AOC 1001)Myotonic Dystrophy Type 1, DM1, Myotonic DystrophyNCT07008469

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13G/ARA Capital Management0.0%May 15, 2026

SC 13G/AAvoro Capital Advisors5.5%Feb 17, 2026

SC 13G/ARA Capital Management5.9%Nov 14, 2025

SC 13D/ARTW Investments3.1%Oct 29, 2025

SC 13G/ARA Capital Management5.4%Nov 14, 2024

SC 13GAvoro Capital Advisors8.3%Nov 14, 2024

SC 13D/ARTW Investments10.0%Aug 23, 2024

SC 13GRA Capital Management5.1%May 6, 2024

SC 13D/ARTW Investments10.0%Mar 1, 2024

SC 13G/ARA Capital Management3.3%Feb 14, 2024

SC 13D/ARTW Investments8.4%Jan 24, 2024

SC 13G/AEcoR1 Capital0.0%Feb 14, 2023

SC 13D/ARTW Investments9.0%Feb 2, 2023

SC 13GRA Capital Management8.2%Dec 30, 2022

SC 13GCormorant Asset Management1.8%Dec 27, 2022

SC 13G/ACormorant Asset Management0.5%Feb 14, 2022

SC 13G/AEcoR1 Capital5.9%Feb 14, 2022

SC 13GEcoR1 Capital5.6%Feb 16, 2021

SC 13G/ACormorant Asset Management1.8%Feb 16, 2021

SC 13GCormorant Asset Management1.9%Jun 26, 2020

SC 13DRTW Investments11.3%Jun 22, 2020

Position Details

Eventide Asset ManagementEXITEDMay 15, 2026

Start free trialfor share counts, dollar values & AI analysis

160 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

ATXS4 funds ACLX3 funds RCKT3 funds BEIGF3 funds ELVN3 funds AXSM3 funds BHVN3 funds RYTM3 funds

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Casdin Capital

6Q